NAS
CORT icon

Nykredit A/S’s Corcept Therapeutics CORT Stock Holding History

Nykredit A/S’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Buy
+3,205
New +$194K ﹤0.01% 904

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's CORT Position: Q2 2026 in Review

Nykredit A/S opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,205 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #904 among its holdings.

323 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Nykredit A/S held 3,205 shares of Corcept Therapeutics worth $279K as of Q2 2026.
  • Corcept Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #904 holding.
  • 323 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.